3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 103 | 2019-09-09 | 2025-01-16 |
| Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia Fosaprepitant 150 mg - Postoperative Nausea | Phase 4 | Completed | Stanford University | 11 | 2018-01-01 | 2022-07-18 |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting fosaprepitant, aprepitant, Oral Placebo - Ovarian Cancer, Uterine Cancer | Phase 4 | Completed | Gynecologic Oncology Associates | 20 | 2011-09-01 | 2017-03-28 |
Vomiting (2) · Ovarian Neoplasms (1) · Postoperative Nausea and Vomiting (1) · Uterine Neoplasms (1)
Gynecologic Oncology Associates (1) · Merck Sharp & Dohme LLC (1) · Stanford University (1)
United States (3) · Greece (1) · Hungary (1) · Lithuania (1) · Netherlands (1) · Peru (1) · Poland (1) · Russia (1) · United Kingdom (1)
John P Micha, MD (1) · Mark A Burbridge, MD (1)
2018 (1)